Creating targeted treatments for Multiple Myeloma using SETD8 inhibitors
Developing Lysine Methyltransferase SETD8 Selective Inhibitors for Treating Multiple Myeloma
This study is looking at new ways to help people with Multiple Myeloma by testing special compounds that can block a protein called SETD8, which helps cancer cells grow, with the hope of making those cells die off more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11221119 on NIH RePORTER |
What this research studies
This research focuses on developing selective inhibitors for SETD8, a protein that plays a crucial role in the growth of Multiple Myeloma (MM) cells. By inhibiting SETD8, the researchers aim to disrupt the cancer cell cycle and promote cell death specifically in MM cells that overexpress this protein. The approach involves testing new compounds that have shown promise in preliminary studies to effectively target and inhibit SETD8, potentially leading to improved treatment options for patients with MM.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with Multiple Myeloma, particularly those with high levels of SETD8 expression.
Not a fit: Patients with other types of cancers or those whose Multiple Myeloma does not involve SETD8 overexpression may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted therapies for patients suffering from Multiple Myeloma.
How similar studies have performed: Other research has shown promising results with similar approaches targeting SETD8 in cancer treatment, indicating potential for success in this area.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Jin, Jian — Icahn School of Medicine at Mount Sinai
- Study coordinator: Jin, Jian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.